Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial.

Abstract

Quality of life in heart failure patients is receiving increased attention as a reflection of a treatment's potential secondary benefit of general well-being and daily functioning. The Metoprolol in Dilated Cardiomyopathy (MDC) trial was conducted as a large, multicenter trial to establish the effects of metoprolol on mortality and need for heart transplantation in patients with symptomatic idiopathic cardiomyopathy. It was found that metoprolol was well tolerated, improved symptoms and cardiac function, and prevented clinical deterioration in patients with symptomatic idiopathic dilated cardiomyopathy. Quality of life was evaluated as a secondary endpoint in 345 out of 383 randomized patients using a disease-specific questionnaire, the Quality of Life in Heart Failure Questionnaire, depicting physical activity, somatic symptoms, emotions, and life satisfaction. In a comparison of patients treated with metoprolol or placebo, patients treated with metoprolol noted a significantly more favorable response than those treated with placebo in terms of the overall treatment evaluation (p < 0.05). Additionally, an analysis of the changes from baseline to 18 months, using 95% confidence intervals, revealed that patients treated with metoprolol showed a significant improvement from baseline to 18 months in life satisfaction, physical activity, and the total score, while patients treated with placebo did not change at all. The improvement in quality of life was supported by the correlations with improvement in traditional clinical parameters.

• Authors: I Wiklund, F Waagstein, K Swedberg, A Hjalmarsson
• Journal: Cardiovascular drugs and therapy (Cardiovasc Drugs Ther) Vol. 10 Issue 3 Pg. 361-8 (Jul 1996) ISSN: 0920-3206 [Print] United States
• PMID: 8877080 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Adrenergic beta-Antagonists
• Metoprolol

Topics

• Adrenergic beta-Antagonists (administration & dosage, pharmacology, therapeutic use)
• Cardiomyopathy, Dilated (drug therapy, mortality)
• Double-Blind Method
• Female
• Humans
• Male
• Metoprolol (administration & dosage, pharmacology, therapeutic use)
• Quality of Life
• Reproducibility of Results
• Stroke Volume (drug effects)
• Surveys and Questionnaires
• Treatment Outcome